How Long Does Donanemab Take to Help Dementia Symptoms?

See what 12-18 months of slowing looks like, which scans guide stopping, and what risks need MRI checks.

Donanemab takes about 12 to 18 months to show a measurable slowing of Alzheimer's symptoms. Donanemab-azbt (Kisunla), a monthly infusion for early symptomatic Alzheimer's, slows decline rather than restoring memory. Families should expect steadier daily function, not improvement.

Pharmacy Times reports FDA approval on July 2, 2024 for adults with mild cognitive impairment or mild dementia plus confirmed amyloid, described in the FDA approval notice. The pivotal trial followed 1,736 people for 76 weeks, about 18 months, according to a European Academy of Neurology summary. That long window explains why doctors wait a year or more to judge benefit.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

Plaque clears fast, thinking changes slowly

A Health Science Reports review reports mean plaque drops of about 61% at 6 months, 80% at 12 months, and 84% at 18 months. Those PET results are detailed in the amyloid-clearance review. Clearance starts early and builds with continued infusions. An Alzheimer's and Dementia review reports 35.1% slowing on daily-function scores and 36% on CDR-Sum of Boxes at 76 weeks.

The low/medium-tau result is summarized in the trial review. Both gaps appeared only after many months of treatment. Think of plaque removal as clearing debris while the brain still works harder. Daily change looks like slower loss of errands, bills, or conversation thread. The trial measured that slower loss over 18 months, not week-to-week gains.

Why you may notice no improvement

A Drugs.com medical answer explains donanemab does not reverse memory loss or stop progression. It only slows how fast Alzheimer's worsens. Benefit is therefore judged over 12 to 18 months, not by feeling sharper. Track small daily tasks rather than test scores at home.

Note dressing, meals, medication timing, and getting lost on familiar routes. Bring dated notes to visits so the care team can compare steady periods and declines. Do not pause or extend infusions because one month feels flat. Early flat months are expected before any group-level gap emerges. Use visit time to review side effects and next scans.

How long treatment lasts

Lilly Medical dosing information lists infusions about every 4 weeks with stepwise doses of 350 mg, then 700 mg, then 1,050 mg, then 1,400 mg. Prescribers consider stopping when PET shows minimal amyloid. The schedule allows plaque checks during treatment, not indefinite dosing by default.

Lilly Medical response information reports 17% met clearance criteria for switching to placebo by week 24, 47% by week 52, and 69% by week 76. Clearance meant under 24.1 Centiloids on PET. Many patients can therefore stop within a year to 18 months if scans confirm clearance.

  • attend every 4-week infusion unless the team pauses it
  • ask when PET checks for minimal amyloid occur
  • confirm stop and follow-up plans in writing

What to weigh before starting

Eli Lilly reports ARIA, swelling or microbleeds seen on imaging, as a common boxed-warning risk. Baseline and periodic MRI monitoring are required, as described in the company safety update. Symptoms occurred in about 6% in the program.

Build monitoring into the decision, not around it. Families need rides, time off, and a plan for urgent calls. Rare fatal events make that monitoring non-optional. Ask the prescribing team how they schedule MRIs and PET checks before the first infusion.

  • baseline MRI before first dose, plus scheduled MRIs during treatment
  • report new symptoms promptly for same-day advice
  • review amyloid PET timing and stop rules at the consent visit

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.